Inovio's Ebola vaccine delivered intradermally demonstrates 100% immunogenicity in trial
Inovio announced that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the advancement of the intradermal delivery platform for infectious diseases. March 21, 2019